Loading...
Epidermal growth factor receptor (EGFR)–targeted agents plus two-drug chemotherapy (e.g., FOLFOX or FOLFIRI) are preferred for use in left-sided RAS and BRAF wild-type metastatic colorectal cancers. When bevacizumab is used, three-drug chemotherapy (e.g., FOLFOXIRI) has trended superior to two-drug chemotherapy. Hepatic resection of liver metastases improves survival, and systemic chemotherapy is used to augment local regional therapy.
The open-label CAIRO5 trial evaluated four chemotherapy regimens in patients with metastatic colorectal cancer with hepatic metastases confined to the liver but potentially resectable, contingent on a response to chemotherapy. Patients with RAS or BRAF mutant cancers or right-sided primary tumors were randomiz…